In a 38-year-old man with recurrent cerebrovascular accidents, incidentally detected hypertension, chronic kidney disease (serum creatinine 1.6 mg/dL), a solitary normal kidney and a dysplastic contracted contralateral kidney, negative antiphospholipid antibodies and complement studies, and a positive antinuclear antibody with U1‑RNP positivity, what autoimmune rheumatic diseases should be considered?

Primary Diagnosis: Mixed Connective Tissue Disease (MCTD)

In this 38-year-old man with recurrent CVA, CKD, hypertension, and positive U1-RNP antibodies (with negative APLA and complements), the primary autoimmune rheumatic disease to consider is Mixed Connective Tissue Disease (MCTD), followed by systemic lupus erythematosus (SLE) as a close differential.

Diagnostic Reasoning

U1-RNP Positivity: The Key Finding

The positive U1-RNP antibody is the critical serological marker here. This antibody is:

• Highly specific for MCTD when present as the predominant or isolated autoantibody
• Also found in approximately 30-40% of SLE patients, but typically alongside other antibodies
• Associated with neuropsychiatric manifestations in both MCTD and SLE 1

The absence of other typical SLE antibodies (negative anti-dsDNA implied by negative complements, negative APLA) makes MCTD more likely than SLE in this presentation.

Clinical Features Supporting MCTD

Your patient's constellation of findings aligns with MCTD:

Cerebrovascular manifestations: U1-RNP antibodies in cerebrospinal fluid show 64.3% sensitivity and 92.9% specificity for central neuropsychiatric disease in U1-RNP-positive patients 1. The recurrent CVAs suggest ongoing CNS vasculopathy, which occurs in both MCTD and SLE.

Renal involvement: While the dysplastic kidney may be congenital, the CKD with creatinine 1.6 and hypertension could represent:

• MCTD-associated renal disease (less common but documented)
• Early lupus nephritis (if this evolves into SLE)
• Renovascular disease from vasculopathy

Hypertension: This is a common feature in both conditions, particularly when renal involvement is present.

Differential Diagnoses to Exclude

1. Systemic Lupus Erythematosus (SLE)

Despite negative APLA and complements, SLE remains on the differential because:

• U1-RNP positivity occurs in 30-40% of SLE cases
• Neuropsychiatric SLE can present with recurrent CVAs 2
• Lupus nephropathy causes CKD and hypertension 2

However, the absence of:

• Anti-dsDNA antibodies (typically causes low complements)
• Antiphospholipid antibodies
• Other typical SLE features makes pure SLE less likely at this time.

2. Antiphospholipid Syndrome (APS)

This has been ruled out by negative APLA testing, but warrants discussion:

• APS commonly causes recurrent CVAs in young patients 3, 4
• APS nephropathy presents with hypertension and CKD 5, 6
• However, your patient's negative APLA testing excludes this diagnosis
• Note: APLA should be retested at 12 weeks to definitively exclude APS 4

3. ANCA-Associated Vasculitis (AAV)

Less likely but should be considered:

• Can cause cerebrovascular disease and CKD 7
• Typically ANCA-positive (MPO or PR3)
• Usually presents with more acute, rapidly progressive GN
• The U1-RNP positivity and clinical pattern don't fit AAV

Essential Additional Workup

Immediate Testing Required:

Complete autoantibody panel:

• Anti-dsDNA, anti-Sm (for SLE)
• Anti-Ro/SSA, anti-La/SSB (overlap syndromes)
• Rheumatoid factor (can be positive in MCTD)
• Repeat ANA with full ENA panel to confirm U1-RNP and exclude other specificities

Complement levels:

• C3, C4, CH50 (you mentioned these were negative, but clarify if this means "normal" or "low")
• Low complements would favor active SLE over MCTD

Repeat APLA testing at 12 weeks:

• Lupus anticoagulant
• Anticardiolipin IgG/IgM
• Anti-β2-glycoprotein I IgG/IgM
• Essential to definitively exclude APS 4

ANCA testing:

• MPO-ANCA and PR3-ANCA to exclude AAV 7

Organ-Specific Evaluation:

Renal assessment:

• Urinalysis with microscopy (dysmorphic RBCs, casts)
• 24-hour urine protein or spot protein/creatinine ratio
• Renal ultrasound with Doppler (assess for renal artery stenosis, which can occur in both MCTD and potential missed APS) 6
• Kidney biopsy if proteinuria >500mg/day or progressive renal dysfunction—essential for distinguishing lupus nephritis from MCTD renal disease

Neurological evaluation:

• MRI brain with contrast (look for acute/chronic infarcts, white matter disease)
• MRA or CTA of cerebral vessels (assess for vasculitis vs. vasculopathy)
• Consider lumbar puncture if active CNS symptoms—CSF anti-U1-RNP antibodies and anti-U1-RNP index can confirm intrathecal antibody production 1

Cardiovascular assessment:

• Echocardiogram (exclude cardioembolic source, assess for pulmonary hypertension common in MCTD)
• ECG

Clinical Pitfalls and Caveats

Critical Considerations:

MCTD can evolve into definite SLE: Up to 30% of MCTD patients eventually meet full SLE criteria. Serial monitoring of antibodies and clinical features is essential.

Negative APLA doesn't exclude future positivity: Antiphospholipid antibodies can develop over time, particularly in SLE patients. The recurrent CVAs are concerning for a thrombotic diathesis—repeat APLA testing at 12 weeks is mandatory 4.

U1-RNP-associated neuropsychiatric disease requires specific management: If CSF shows intrathecal anti-U1-RNP production, this indicates active CNS involvement requiring immunosuppression 1. The cerebrovascular events may be inflammatory (requiring immunosuppression) rather than purely thrombotic 2.

The dysplastic kidney complicates interpretation: Congenital renal anomalies can cause hypertension and CKD independent of autoimmune disease. However, the combination with recurrent CVAs and U1-RNP positivity suggests systemic autoimmune disease is contributing.

Management Approach

Immediate Actions:

Stroke prevention:

• Antiplatelet therapy (aspirin 81mg daily) given recurrent CVAs and negative APLA
• Aggressive blood pressure control (target <130/80 mmHg given CKD and CVA history)
• Statin therapy for secondary prevention

Immunosuppression consideration: If neuroimaging/CSF suggests inflammatory CNS vasculopathy rather than bland infarcts:

• Glucocorticoids (prednisone 0.5-1 mg/kg/day) 2
• Consider adding steroid-sparing agent (azathioprine, mycophenolate, or methotrexate) depending on renal function and biopsy results 2

Renal protection:

• ACE inhibitor or ARB if proteinuric (hold if creatinine rises >30%)
• Optimize blood pressure control
• Avoid nephrotoxins

Long-term Monitoring:

• Serial autoantibody testing every 3-6 months
• Repeat APLA at 12 weeks
• Regular urinalysis and renal function monitoring
• Periodic neurological assessment
• Monitor for development of other MCTD/SLE features (arthritis, myositis, Raynaud's, sicca symptoms)

The diagnosis of MCTD should be made in consultation with rheumatology, with SLE remaining a close differential requiring ongoing surveillance for evolution of the clinical and serological picture.